Revere Increases Data Focus on Canadian BioPharm, MedTech Stocks
The data, which includes information on companies' product pipelines, the status of clinical trials, and information on companies' relationships to competitors and suppliers, is being made available via the vendor's Revere Research analysis platform and Revere RealTime data system. The data is also available as part of the vendor's XML or CSV file-format Healthcare Events datafeed, which can be fed directly into firms' databases or trading models, such as for index or statistical arbitrage
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
The market’s most valuable asset?
DTCC’s Tim Lind writes that using data effectively can provide the intelligence needed to improve investment performance, reduce risk, and inform strategic decision‑making.
Report once: will Esma’s €1bn reforms deliver the full picture?
Critics say plan to merge three reporting regimes will see scant returns, and won’t mesh with single-sided reporting.
Navigating the MarketAxess ICE storm
The Waters Wrap: Most of the discussion surrounding ICE’s MarketAxess buy has focused more on benefits for the front office than the data possibilities.
CTA, UTP to merge into single Consolidated Tape Plan under DataCT
Randall Hopkins, former head of market data at Nasdaq, will join the new company to build and run it.
Managing regulatory transformation through a Dual-Flow Operating Model
Darshan Shah presents an operating model that enables project teams to implement complex regulatory programs, preserve business continuity, reduce risk, and prepare enterprise platforms for regulatory change.
SEC denies 24X’s requested SIP exemption, for now
Start-up exchange cannot begin its overnight market session before the equity data plans’ hours are scheduled to be extended on December 6. But that’s only half of it.
LSEG–MayStreet lawsuit may have precedent in Delaware court
Lawyers for Patrick Flannery argue that a recently settled case in Delaware sets precedent for his ongoing battle with the exchange group.
A tidal wave of token costs threatens landfall
Budgeting for AI was never “easy,” but as financial firms rely more heavily on agents, soaring token usage is forcing them to rethink the economics of modern enterprise AI.
